Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NYSE:MRX

Medicis Pharmaceutical (MRX) Stock Price, News & Analysis

Medicis Pharmaceutical logo

About Medicis Pharmaceutical Stock (NYSE:MRX)

Advanced Chart

Key Stats

Today's Range
$32.54
$33.33
50-Day Range
N/A
52-Week Range
$18.13
$49.34
Volume
415,945 shs
Average Volume
644,091 shs
Market Capitalization
$2.48 billion
P/E Ratio
N/A
Dividend Yield
1.59%
Price Target
$45.14
Consensus Rating
Moderate Buy

Company Overview

Medicis Pharmaceutical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
23rd Percentile Overall Score

MRX MarketRank™: 

Medicis Pharmaceutical scored higher than 23% of companies evaluated by MarketBeat, and ranked 855th out of 935 stocks in the finance sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Medicis Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Medicis Pharmaceutical has only been the subject of 2 research reports in the past 90 days.

  • Read more about Medicis Pharmaceutical's stock forecast and price target.
  • Earnings Growth

    Earnings for Medicis Pharmaceutical are expected to decrease by -0.34% in the coming year, from $2.94 to $2.93 per share.

  • Short Interest

    There is no current short interest data available for MRX.
  • Dividend Yield

    Medicis Pharmaceutical pays a meaningful dividend of 1.44%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Medicis Pharmaceutical does not have a long track record of dividend growth.

  • Dividend Sustainability

    Based on earnings estimates, Medicis Pharmaceutical will have a dividend payout ratio of 19.11% next year. This indicates that Medicis Pharmaceutical will be able to sustain or increase its dividend.

  • Read more about Medicis Pharmaceutical's dividend.
  • Short Interest

    There is no current short interest data available for MRX.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Medicis Pharmaceutical this week, compared to 1 article on an average week.
  • Search Interest

    Only 6 people have searched for MRX on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.
Receive MRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicis Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MRX Stock News Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.tc pixel
See More Headlines

MRX Stock Analysis - Frequently Asked Questions

Medicis Pharmaceutical Corp (NYSE:MRX) announced its quarterly earnings data on Wednesday, August, 13th. The healthcare company reported $1.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.93 by $0.09. The company's quarterly revenue was up 18.5% compared to the same quarter last year.

Medicis Pharmaceutical (MRX) raised $292 million in an IPO on Thursday, April 25th 2024. The company issued 15,384,615 shares at a price of $19.00 per share.

Top institutional investors of Medicis Pharmaceutical include State of Tennessee Department of Treasury (0.17%), SG Americas Securities LLC (0.03%) and Simplex Trading LLC.

Based on aggregate information from My MarketBeat watchlists, some other companies that Medicis Pharmaceutical investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Record date for 6/10 Dividend
5/27/2025
Ex-Dividend for 6/10 Dividend
5/27/2025
Dividend Payable
6/10/2025
Last Earnings
8/13/2025
Record date for 9/11 Dividend
8/26/2025
Ex-Dividend for 9/11 Dividend
8/26/2025
Today
8/29/2025
Dividend Payable
9/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Finance
Industry
Security & commodity brokers, dealers, exchanges & services
Sub-Industry
N/A
Current Symbol
NYSE:MRX
CIK
859368
Fax
N/A
Employees
2,074
Year Founded
N/A

Price Target and Rating

High Price Target
$54.00
Low Price Target
$34.00
Potential Upside/Downside
+26.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
1.18
Current Ratio
1.04
Quick Ratio
1.08

Sales & Book Value

Annual Sales
$1.24 billion
Price / Sales
2.02
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
70,290,000
Free Float
67,627,000
Market Cap
$2.51 billion
Optionable
Optionable
Beta
N/A
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NYSE:MRX) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners